WO2002034041A1 - Animal non humain a proteine-marqueur de la senescence 30 defectueuse, anticorps et son procede de production - Google Patents
Animal non humain a proteine-marqueur de la senescence 30 defectueuse, anticorps et son procede de production Download PDFInfo
- Publication number
- WO2002034041A1 WO2002034041A1 PCT/JP2001/009243 JP0109243W WO0234041A1 WO 2002034041 A1 WO2002034041 A1 WO 2002034041A1 JP 0109243 W JP0109243 W JP 0109243W WO 0234041 A1 WO0234041 A1 WO 0234041A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- smp30
- antibody
- gene
- deficient
- human animal
- Prior art date
Links
- 241001465754 Metazoa Species 0.000 title claims abstract description 65
- 238000000034 method Methods 0.000 title claims abstract description 65
- 108090000623 proteins and genes Proteins 0.000 title claims description 159
- 102000004169 proteins and genes Human genes 0.000 title claims description 41
- 239000003550 marker Substances 0.000 title description 6
- 230000009758 senescence Effects 0.000 title description 2
- 101000582767 Homo sapiens Regucalcin Proteins 0.000 claims abstract description 46
- 102100030262 Regucalcin Human genes 0.000 claims abstract description 33
- 108091028043 Nucleic acid sequence Proteins 0.000 claims abstract description 22
- 230000002759 chromosomal effect Effects 0.000 claims abstract description 14
- 238000012217 deletion Methods 0.000 claims abstract description 12
- 230000037430 deletion Effects 0.000 claims abstract description 12
- 230000002950 deficient Effects 0.000 claims description 97
- 241000282414 Homo sapiens Species 0.000 claims description 55
- 241000699670 Mus sp. Species 0.000 claims description 39
- 239000012634 fragment Substances 0.000 claims description 36
- 241000699666 Mus <mouse, genus> Species 0.000 claims description 31
- 238000004519 manufacturing process Methods 0.000 claims description 29
- 102000036639 antigens Human genes 0.000 claims description 26
- 108091007433 antigens Proteins 0.000 claims description 26
- 150000001413 amino acids Chemical class 0.000 claims description 24
- 239000000427 antigen Substances 0.000 claims description 24
- 241000700159 Rattus Species 0.000 claims description 23
- 230000003053 immunization Effects 0.000 claims description 21
- 241000283973 Oryctolagus cuniculus Species 0.000 claims description 17
- 241000282472 Canis lupus familiaris Species 0.000 claims description 13
- 230000014509 gene expression Effects 0.000 claims description 13
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 13
- 241000282412 Homo Species 0.000 claims description 12
- 230000008569 process Effects 0.000 claims description 11
- 241000124008 Mammalia Species 0.000 claims description 10
- 238000003780 insertion Methods 0.000 claims description 10
- 230000037431 insertion Effects 0.000 claims description 10
- 229930193140 Neomycin Natural products 0.000 claims description 8
- 241000251539 Vertebrata <Metazoa> Species 0.000 claims description 8
- 230000007812 deficiency Effects 0.000 claims description 8
- 210000004408 hybridoma Anatomy 0.000 claims description 8
- 238000002649 immunization Methods 0.000 claims description 8
- 229960004927 neomycin Drugs 0.000 claims description 8
- 241000283984 Rodentia Species 0.000 claims description 7
- 101000980463 Treponema pallidum (strain Nichols) Chaperonin GroEL Proteins 0.000 claims description 7
- 102000048028 human RGN Human genes 0.000 claims description 7
- 241000272875 Ardeidae Species 0.000 claims description 6
- 206010059866 Drug resistance Diseases 0.000 claims description 6
- 101100412696 Rattus norvegicus Rgn gene Proteins 0.000 claims description 5
- 238000007792 addition Methods 0.000 claims description 5
- 238000012545 processing Methods 0.000 claims description 5
- 238000006467 substitution reaction Methods 0.000 claims description 5
- 241000283086 Equidae Species 0.000 claims description 2
- 241001137251 Corvidae Species 0.000 claims 1
- 102000002274 Matrix Metalloproteinases Human genes 0.000 claims 1
- 108010000684 Matrix Metalloproteinases Proteins 0.000 claims 1
- 230000000474 nursing effect Effects 0.000 claims 1
- 230000007547 defect Effects 0.000 abstract description 2
- 210000004027 cell Anatomy 0.000 description 59
- 230000006801 homologous recombination Effects 0.000 description 20
- 238000002744 homologous recombination Methods 0.000 description 20
- 230000006870 function Effects 0.000 description 17
- 125000003275 alpha amino acid group Chemical group 0.000 description 16
- 108020004414 DNA Proteins 0.000 description 14
- 241000894007 species Species 0.000 description 12
- 210000000349 chromosome Anatomy 0.000 description 11
- 238000003752 polymerase chain reaction Methods 0.000 description 10
- 239000002299 complementary DNA Chemical group 0.000 description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 8
- 239000000047 product Substances 0.000 description 8
- 230000009257 reactivity Effects 0.000 description 8
- 210000000056 organ Anatomy 0.000 description 7
- 201000010099 disease Diseases 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 241000271566 Aves Species 0.000 description 5
- 230000032683 aging Effects 0.000 description 5
- 238000010171 animal model Methods 0.000 description 5
- 230000007423 decrease Effects 0.000 description 5
- 230000003834 intracellular effect Effects 0.000 description 5
- 230000035772 mutation Effects 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 230000008685 targeting Effects 0.000 description 5
- 102100036250 GPI mannosyltransferase 4 Human genes 0.000 description 4
- 101001074618 Homo sapiens GPI mannosyltransferase 4 Proteins 0.000 description 4
- 239000012980 RPMI-1640 medium Substances 0.000 description 4
- 238000002105 Southern blotting Methods 0.000 description 4
- 238000010586 diagram Methods 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 230000004927 fusion Effects 0.000 description 4
- 238000009396 hybridization Methods 0.000 description 4
- 230000016784 immunoglobulin production Effects 0.000 description 4
- 238000011813 knockout mouse model Methods 0.000 description 4
- 239000013612 plasmid Substances 0.000 description 4
- 230000006798 recombination Effects 0.000 description 4
- 238000005215 recombination Methods 0.000 description 4
- 108091008146 restriction endonucleases Proteins 0.000 description 4
- 238000012216 screening Methods 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 238000013519 translation Methods 0.000 description 4
- 101150110188 30 gene Proteins 0.000 description 3
- 238000002965 ELISA Methods 0.000 description 3
- 241000287828 Gallus gallus Species 0.000 description 3
- 206010028980 Neoplasm Diseases 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 201000011510 cancer Diseases 0.000 description 3
- 230000003915 cell function Effects 0.000 description 3
- 235000013330 chicken meat Nutrition 0.000 description 3
- 210000001671 embryonic stem cell Anatomy 0.000 description 3
- 210000002257 embryonic structure Anatomy 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 210000003494 hepatocyte Anatomy 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- 210000001161 mammalian embryo Anatomy 0.000 description 3
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- 108700024394 Exon Proteins 0.000 description 2
- 108700039691 Genetic Promoter Regions Proteins 0.000 description 2
- 102000018071 Immunoglobulin Fc Fragments Human genes 0.000 description 2
- 108010091135 Immunoglobulin Fc Fragments Proteins 0.000 description 2
- 101100412692 Mus musculus Rgn gene Proteins 0.000 description 2
- 206010035226 Plasma cell myeloma Diseases 0.000 description 2
- 210000001766 X chromosome Anatomy 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000000692 anti-sense effect Effects 0.000 description 2
- 210000000628 antibody-producing cell Anatomy 0.000 description 2
- 230000008827 biological function Effects 0.000 description 2
- 210000002459 blastocyst Anatomy 0.000 description 2
- 210000001124 body fluid Anatomy 0.000 description 2
- 239000010839 body fluid Substances 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 230000004094 calcium homeostasis Effects 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- 239000013611 chromosomal DNA Substances 0.000 description 2
- 238000010367 cloning Methods 0.000 description 2
- 238000012790 confirmation Methods 0.000 description 2
- 239000000470 constituent Substances 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 235000013601 eggs Nutrition 0.000 description 2
- 238000004520 electroporation Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000000835 fiber Substances 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 238000010353 genetic engineering Methods 0.000 description 2
- 210000004602 germ cell Anatomy 0.000 description 2
- 125000005842 heteroatom Chemical group 0.000 description 2
- 230000002163 immunogen Effects 0.000 description 2
- 238000000691 measurement method Methods 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 201000000050 myeloid neoplasm Diseases 0.000 description 2
- 239000002773 nucleotide Substances 0.000 description 2
- 125000003729 nucleotide group Chemical group 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 239000000523 sample Substances 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 238000013518 transcription Methods 0.000 description 2
- 230000035897 transcription Effects 0.000 description 2
- 210000004291 uterus Anatomy 0.000 description 2
- 238000001262 western blot Methods 0.000 description 2
- 206010003445 Ascites Diseases 0.000 description 1
- 241000269420 Bufonidae Species 0.000 description 1
- 238000011740 C57BL/6 mouse Methods 0.000 description 1
- 102000005701 Calcium-Binding Proteins Human genes 0.000 description 1
- 108010045403 Calcium-Binding Proteins Proteins 0.000 description 1
- 101710205660 Calcium-transporting ATPase Proteins 0.000 description 1
- 101710134161 Calcium-transporting ATPase sarcoplasmic/endoplasmic reticulum type Proteins 0.000 description 1
- 108091026890 Coding region Proteins 0.000 description 1
- 238000012270 DNA recombination Methods 0.000 description 1
- 241000238557 Decapoda Species 0.000 description 1
- 102000016607 Diphtheria Toxin Human genes 0.000 description 1
- 108010053187 Diphtheria Toxin Proteins 0.000 description 1
- 241000588722 Escherichia Species 0.000 description 1
- 102100028314 Filaggrin Human genes 0.000 description 1
- 101710088660 Filaggrin Proteins 0.000 description 1
- -1 G418 Natural products 0.000 description 1
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 1
- 108060001084 Luciferase Proteins 0.000 description 1
- 241000283203 Otariidae Species 0.000 description 1
- 101000702488 Rattus norvegicus High affinity cationic amino acid transporter 1 Proteins 0.000 description 1
- 108050007056 Regucalcin Proteins 0.000 description 1
- 108700008625 Reporter Genes Proteins 0.000 description 1
- 238000011579 SCID mouse model Methods 0.000 description 1
- 235000002595 Solanum tuberosum Nutrition 0.000 description 1
- 244000061456 Solanum tuberosum Species 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 239000004098 Tetracycline Substances 0.000 description 1
- 108020004440 Thymidine kinase Proteins 0.000 description 1
- 108091023045 Untranslated Region Proteins 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000004520 agglutination Effects 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 230000002823 anti-activator Effects 0.000 description 1
- 230000003466 anti-cipated effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 210000000941 bile Anatomy 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000032677 cell aging Effects 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000007910 cell fusion Effects 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 208000031513 cyst Diseases 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 238000009509 drug development Methods 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 210000001339 epidermal cell Anatomy 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 238000010230 functional analysis Methods 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 239000011491 glass wool Substances 0.000 description 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 238000001114 immunoprecipitation Methods 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 101150066555 lacZ gene Proteins 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 210000005229 liver cell Anatomy 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 230000013011 mating Effects 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 238000000520 microinjection Methods 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 210000003101 oviduct Anatomy 0.000 description 1
- 230000036542 oxidative stress Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 230000001323 posttranslational effect Effects 0.000 description 1
- 235000012015 potatoes Nutrition 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000001850 reproductive effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 238000011896 sensitive detection Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000002689 soil Substances 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 210000004989 spleen cell Anatomy 0.000 description 1
- 210000004988 splenocyte Anatomy 0.000 description 1
- 229910001220 stainless steel Inorganic materials 0.000 description 1
- 239000010935 stainless steel Substances 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 229960002180 tetracycline Drugs 0.000 description 1
- 229930101283 tetracycline Natural products 0.000 description 1
- 235000019364 tetracycline Nutrition 0.000 description 1
- 150000003522 tetracyclines Chemical class 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000009261 transgenic effect Effects 0.000 description 1
- 210000004926 tubular epithelial cell Anatomy 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 108700026220 vif Genes Proteins 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/027—New or modified breeds of vertebrates
- A01K67/0275—Genetically modified vertebrates, e.g. transgenic
- A01K67/0276—Knock-out vertebrates
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/07—Animals genetically altered by homologous recombination
- A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2227/00—Animals characterised by species
- A01K2227/10—Mammal
- A01K2227/105—Murine
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
Definitions
- the present invention provides an animal of a novel strain deficient in the function of senescence marker protein 30 (hereinafter referred to as "SMP30"), a method for producing the same, and an antibody produced using the animal according to the present invention. About the production method.
- SMP30 senescence marker protein 30
- genes and gene product-deficient mice can be produced in ES cells (Embryonic Stem Cells) by using homologous recombination of genes (Koller et al.). Natl. Acad. Sci. USA, Vol. 86, pp. 8927-8931, 1989).
- a gene encoding a target protein is disrupted. Specifically, the target gene to be destroyed is cloned, and an evening getter vector to be inserted into the gene is created. This vector is introduced into mouse ES cells and homologous recombination takes place.
- the recombinant ES cells are adsorbed to the 8-cell embryo of the fertilized egg, transplanted into the fallopian tubes of a pseudopregnant in advance, and born. D from the tail of the mouse born later
- the NA is extracted, and recombination of the target gene is confirmed by PCR (Polymerase Chain Reaction) or Southern hybridization. This mouse is further bred to establish a pure knockout mouse strain.
- the disrupted gene is not necessarily limited to the gene encoding the target protein. For a particular gene, one of a series of steps from its transcription to translation, or any of the steps if post-translational processing is required for the gene product (protein) to function properly. Modification of a gene that inhibits the protein also results in deletion of the protein. In this case, depending on which process is inhibited, the protein exhibits various phenotypes such as no production of the protein or no function even if produced.
- the gene disrupted by the foreign gene is usually incorporated into all cells, including germ cells, and is accurately transmitted to offspring according to Mendel's law. That is, newly created knockout mice can be established as one new strain, and as long as their reproductive ability is not impaired, they can be continuously supplied as experimental animals with the same genetic qualities by repeated mating. It is possible. In addition, by connecting a gene regulatory region such as a promoter to enhance the gene to be introduced, tissue-specific expression can be controlled. On the other hand, the production and use of antibodies that are indispensable for biological analysis has a long history, and methods for producing monoclonal antibodies have been reported in 1975.
- SMP30 was reported in 1992 as a protein in rat hepatocytes that decreases with age (Fujita et al., Biochim Biophys Acta, Vol. 1 116, 122-128, 1992), and its amino acid sequence and cDNA sequence are also human. (Fujita et al., Biochim Biophys Acta, Vol. 1263, 249-252, 1995), rat (Fujita et al., Biochim Biophys Acta ⁇ Vol. 132, 297-305, 1992), mouse (Fujita et al., Biochim Biophys ⁇ , Vol.
- Intracellular calcium is an essential ion for various cell functions, but an excessive increase significantly reduces cell functions including cell membrane damage. Therefore, maintenance of intracellular calcium homeostasis is essential for maintaining cell function.
- SMP30 is a new type of calcium-binding protein that is known to have a biological function of maintaining intracellular calcium homeostasis by activating the cell membrane calcium pump.
- the details and mechanisms of the function of SMP30 in species including humans have not been fully elucidated, and there are many points that need to be elucidated, particularly in relation to diseases and involvement in various disease states. I have.
- it is essential to provide an animal model deficient in SMP30.
- the present inventor prepared an anti-human SMP30 polyclonal antibody by immunizing a egret with human SMP30 (Japanese Patent Application Laid-Open No. 7-97399).
- an object of the present invention is to provide a non-human animal deficient in SMP30.
- Another object of the present invention is to provide a highly reactive anti-SMP30 antibody that could not be produced by conventional techniques, and to provide means for producing the same. Disclosure of the invention
- the inventors of the present application failed to produce a highly reactive anti-human SMP30 monoclonal antibody / anti-human SMP30 monoclonal antibody in the prior art.
- the cause was thought to be that the amino acid sequence of SMP30 had a high degree of homology between different species. In other words, healthy animal individuals do not produce antibodies against their own proteins (immunologic tolerance). Therefore, immunization with a protein from a heterologous animal that is highly homologous to the self protein of the animal does not produce an antibody against a portion homologous to the self protein due to tolerance. Acted as an immunogen, which led to the idea that the resulting polyclonal antibody had low reactivity and the probability of obtaining a monoclonal antibody was extremely low.
- the first aspect of the SMP30-deficient non-human animal of the present invention is a non-human animal deficient in SMP30 function.
- the deficiency of the function of the SMP30 causes deletion of at least a part of the DNA sequence or insertion of another sequence in the chromosomal SMP30 gene. Or replacing at least a portion of the DNA sequence with another sequence, or a combination thereof. SMP30 deficient non-human animal.
- a third aspect of the SMP30-deficient non-human animal of the present invention is a gene encoding a gene product in which the deficiency of SMP30 function is involved in the process of chromosomal SMP30 gene expression or the process of SMP30 processing. Deleting at least a part of the DNA sequence, inserting another sequence, or replacing at least a part of the DNA sequence with another sequence, or a combination thereof. SMP30 deficient non-human animal.
- a fourth aspect of the SMP30-deficient non-human animal of the present invention is an SMP30-deficient non-human animal, wherein the other sequence is a drug resistance gene.
- a fifth aspect of the SMP30-deficient non-human animal of the present invention is characterized in that the drug resistance gene is a neomycin resistance gene inserted into an exon of a chromosomal SMP30 gene, Animal.
- a sixth aspect of the SMP30 deficient non-human animal of the present invention is an SMP30 deficient non-human animal, wherein the SMP30 deficient non-human animal is a mammal.
- a seventh aspect of the SMP30-deficient non-human animal of the present invention is an SMP30-deficient non-human animal, wherein the SMP30-deficient non-human animal is a rodent.
- An eighth aspect of the SMP30-deficient non-human animal of the present invention is an SMP30-deficient non-human animal, wherein the SMP30-deficient non-human animal is mouse 1 .
- the present invention further provides an anti-SMP30 antibody having a high antibody titer obtained by immunizing a non-human animal deficient in SMP30. That is, a first embodiment of the antibody of the present invention is an antibody which is obtained by immunizing a non-human animal deficient in SMP30 with SMP30 and has SMP30 or a partial peptide thereof as an antigen.
- a second aspect of the antibody of the present invention is an antibody obtained by immunizing any of the above-described SMP30-deficient non-human animals and having SMP30 or a partial peptide thereof as an antigen.
- a third aspect of the antibody of the present invention is an antibody characterized by using vertebrate SMP30 or a partial peptide thereof or vertebrate partial SMP30 or a partial peptide thereof as a common antigen. is there.
- a fourth embodiment of the antibody of the present invention is an antibody, wherein the vertebrate is a mammal.
- the fifth embodiment of the antibody of the present invention is characterized in that the antibody is immunized with SMP30 of any one of mice, rats, humans, rabbits, rabbits, dogs, dogs, and horses or a partial peptide thereof.
- the obtained antibody is used for mouse, rat, human, rabbit, egret, rabbit, dog, dog, and all or all of them, SMP30 or a part thereof. Is a common antigen.
- a sixth embodiment of the antibody of the present invention is a mouse, rat, human, rabbit, mouse, dog, dog, bush, and kael obtained by immunizing rat SMP30 with SMP30-deficient mice.
- An antibody characterized in that SMP30 or a partial peptide thereof is used as a common antigen.
- a seventh aspect of the antibody of the present invention is an antibody characterized in that the anti-SMP30 antibody is obtained by immunization with SMP30 modified by addition, substitution, deletion, or insertion of amino acids. is there.
- An eighth aspect of the antibody of the present invention is an antibody, wherein the above antibody is a polyclonal antibody.
- a ninth aspect of the antibody of the present invention is an antibody, wherein the antibody is a monoclonal antibody or an antigen-binding fragment thereof.
- fragment refers to an antigen-binding fragment, and does not include a fragment that does not bind to an antigen (eg, Fc fragment).
- the present invention also provides a method for producing an SMP30-deficient non-human animal.
- the first embodiment of the method for producing an SMP30-deficient non-human animal of the present invention comprises deleting at least a part of the DNA sequence of the chromosomal SMP30 gene, inserting another sequence, or at least A method for producing an SMP30-deficient animal, comprising producing a mutant SMP30 gene whose function has been lost by replacing a part of the DNA sequence with another sequence, or by combining these sequences. It is.
- the second embodiment of the method for producing an SMP30-deficient non-human animal of the present invention comprises at least a part of a gene encoding a gene product involved in the process of expression of the chromosomal SMP30 gene or the process of SMP30 processing.
- the present invention relies on an antibody method in which homology between species is not high or the antibody cannot be produced with high antibody titer. That is, the first aspect of the antibody spotting method according to the present invention is the production of an anti-SMP30 antibody using SMP30 or a part thereof as an antigen, based on immunization of a non-human animal deficient in SMP30.
- the above-mentioned anti-SMP3 antibody comprises any one of the above-mentioned SMP30-deficient non-human animals using any of the above-mentioned SMP30-deficient non-human animals.
- This is a method for producing antibodies.
- the third! ⁇ of the antibody production method of the present invention is that the antibody produced by the above-described method is polyclonal. This is a method for producing an anti-SMP30 antibody that is a null antibody or a monoclonal antibody or its original fragment.
- the antibody of the present invention, the anti-activator method of the present invention, Iitani, Jit is a monoclonal antibody or a monoclonal antibody thereof, wherein the antibody obtained by the above-described method shows human SMP30 or SJiT. This is a method that assumes that it is a sex fragment.
- the first aspect of the hybridoma immunization method of the present invention comprises an anti-SMP30 antibody hybridoma which immunizes an SMP30 deficient non-human animal and makes the SMP30 or its 3 ⁇ 4 a ⁇ .
- the second aspect of the hybridoma production S3 ⁇ 4 method according to the present invention is that the anti-SMP30 antibody, which is described by the above-mentioned dipridoma, is any of the antibodies of the above-mentioned B®.
- the present invention is not limited to SMP30, but also provides an HIS-like method for antibody leakage that leaks proteins showing high homology between species.
- Production of Antibodies of the Present Invention! ⁇ ⁇ ⁇ ⁇ ya's Fiber is an antibody or a fiber thereof containing an amino acid having a homology of 40% or more between amino acids between vertebral shelves. It is illegal, however, to immunize an animal deficient in the primordium to produce an antibody or a fangogenic fragment thereof against the primordium.
- the present invention is particularly effective when the amino acid homology between spinal ⁇ products is 50% or more: ⁇
- another method for producing the antibody of the present invention is a method for preparing an antibody of the invention between mammals.
- a method for preparing an antibody or its binding I 'live fragment, which observes amino acids having amino acid homology of 50% or more, and immunizing a three-membered animal of The present invention relates to a method for producing an antibody against ⁇ or its source 1 ⁇ 1 'raw fragment.
- the present invention is particularly effective when the amino acid homology between flL animals is 60% or more. L If the homology between animals is 60%, the homology between the animals is higher than that of the burp (Xya has a higher homology). This is an extremely effective means for producing an antibody of the cytoplasm preserved in the above.
- FIG. 1 is a schematic diagram of the SMP30 gene cloned from a 129ZSv mouse.
- Fig. 2 shows the promoter containing the promoter used in the construction of the targeting vector.
- Figure 3 is a conceptual diagram of the preparation of the evening-getting vector.
- FIG. 4 is a schematic diagram of a PCR system for detecting homologous recombination.
- FIG. 5 shows the genotypes and phenotypes of the first to third generations of SMP30 gene-deficient mice.
- the cDNA of the SMP30 gene has been cloned from humans, mice, rats, rabbits, rabbits, sea lions, chickens, chickens, etc., and the cDNA sequence and the amino acid sequence of the encoded protein (SMP30) have been reported. (Fujita et al. Or Misawa et al., Mentioned above). In mice, the structure of the chromosomal SMP30 gene has also been reported (Fujita et al., Biochim Biophys Vol. 1308, 49-57, 1996).
- SMP30s consist of 299 amino acids and show a high homology of about 70% to 92%, especially 89% in mice and humans and 94% in mice and rats (Fujita et al., Biochim Biophys. Vol. 1308, 49-57, 1996).
- SMP30 or the SMP30 gene encoding the same may be a previously reported amino acid sequence of SMP30 in humans, mice, rats, rabbits, rabbits, mice, chickens, etc., a cDNA sequence of the SMP30 gene, or a dienomic. As long as they have homology to the DNA sequence, those other than those already reported and those other than those derived from animals are also included.
- SMP30 or the SMP30 gene encoding it include, for example, (1) NCBI accession number Q64374 (European Molecular Biolaby Laboratory (EMB) L) a protein having the amino acid sequence of the mouse described in (SEQ ID No. 1) or a gene encoding the same; (2) a mouse having the previously reported NCBI accession number Q64374 (EMBL); A protein having an amino acid in which one or several amino acid residues are added, deleted or substituted in the amino acid sequence (SEQ ID No. 1), or a gene encoding the same.
- the addition, deletion, or substitution of amino acids is usually 1 to about 90, preferably 1 to about 60, more preferably 1 to about 30, still more preferably 1 to about 15, and still more preferably One to several.
- SMP 30 in the present invention is usually 70% or more, preferably 80% or more, more preferably 70% or more of the previously reported mouse amino acid sequence described in NCB I access number Q64374 (EMBL) (SEQ ID No. 1). Has an amino acid sequence homology of 90% or more, more preferably 95% or more.
- the homology of amino acid sequences can be easily calculated using well-known computer software such as FASTA, and such software is also used by INN Yuichi Net.
- the SMP30 gene cDNA in the present invention is usually 60% or more, preferably 70% or more, more preferably 70% or more, with the cDNA sequence described in NCB I access number U28937 (DDBJ) (SEQ ID No: 2). It has 80% or more, more preferably 90% or more nucleotide sequence homology.
- SMP30 deficiency Means a non-human animal that does not produce SMP30 due to a mutation introduced into the chromosome, or that produces a mutant SMP30 with a defective function.
- SMP30 deficiency is most commonly caused by having a mutant SMP30 gene whose function is deficient, and methods have been established for genetic engineering. In the present invention, the insertion of another sequence (sequence different from the original sequence of the gene)
- An SMP30-deficient animal having a mutant SMP30 gene according to the present invention is given as an example of the implementation.
- SMP 30 deficiency is not necessarily limited to mutations in the chromosomal SMP 30 gene.
- a mutant SMP30 gene with a defective function includes a gene in which gene expression is suppressed or gene product activity is at least partially lost as compared to a normal gene without mutation.
- a typical example is a gene in which gene expression is completely suppressed or gene product activity is completely lost.
- the mutant SMP30 gene is present in a homozygous state on the chromosome (homodeficient animal) or in a heterozygous state in all of the constituent cells. (Hetero-deficient animals). Also, a chimeric animal in which the mutant SMP30 gene is present in a homozygous or heterozygous state in only a part of its constituent cells is included.
- Non-human animals include, for example, mammals such as mice, rats, egrets, and bushes, birds such as birds, and amphibians such as potatoes. Among them, rodents such as mouse and rat are preferred because they have short life cycle and are easy to breed, and are advantageous in that they have established technology for producing genetically deficient animals. .
- the SMP30-deficient animals of the present invention are most commonly used for chromosomal SMP3 It can be produced by artificially introducing a mutation into the 0 gene and deleting its function. Specifically, the function of the SMP30 gene is deleted by deleting at least a portion of the DNA sequence of the SMP30 gene on the chromosome, inserting another sequence, or substituting another sequence. Can be deleted.
- the site where the deletion or other sequence is inserted (substituted) (target site) may be any of the promoter region, untranslated region, and translated region in the SMP30 gene. Depending on which of these parts is targeted, the transcript (mRNA) of the SMP30 gene can no longer be produced or the transcript can be destabilized.
- SMP30 protein
- fragments thereof can also produce inactivated SMP30 (protein) and fragments thereof.
- the promoter region or the translation region is preferable to use the promoter region or the translation region as a target.
- Mutation introduction into the SMP30 gene on the chromosome as described above can be performed by homologous recombination of the gene. Specifically, for example, it can be implemented as follows.
- an evening getter vector to be used for homologous recombination is prepared.
- the evening getting vector contains all or a part of the chromosome-derived SMP30 gene to be replaced by homologous recombination and a marker gene.
- the upstream and downstream of the marker gene are surrounded by a nucleotide sequence site homologous to the insertion site of the SMP30 gene.
- All or part of the SMP30 gene can be obtained by isolating the SMP30 gene region from chromosomal DNA of an animal species in which the SMP30 gene is to be deleted.
- SMP can be performed from the chromosome DNA (DNA) library of the animal species by PCR using the polymerase chain reaction (PCR), colony hybridization, plaque hybridization, or a combination thereof. 30 gene clones can be obtained. In the evening-getting vector, insert the marker gene. This is the vector This is for selecting only the introduced cells when-is introduced into the cells.
- Such marker genes include, for example, the neomycin resistance gene (neo), the diphtheria toxin A fragment gene (DT-A), the iglomycin resistance gene, the tetracycline resistance gene, the streptomycin resistance gene, and the herpes swirl thymidine kinase gene (HSV Genes used for normal drug resistance selection, such as -tk), can be used.
- neomycin resistance gene neo
- DT-A diphtheria toxin A fragment gene
- iglomycin resistance gene the tetracycline resistance gene
- streptomycin resistance gene the herpes swirl thymidine kinase gene
- HSV Genes used for normal drug resistance selection such as -tk
- cells into which the neomycin resistance gene has been introduced show resistance to neomycin such as G418, so that by adding neomycin during cell culture, only cells containing the vector can be selected.
- a repo overnight gene may be
- the repo overnight gene may be a commonly used gene, such as the lacZ (Escherichia coli-galactosidase) gene, the CAT (chloramphenic acid acetylacetyltransferase) gene, the GUS (? -Gluconidase) gene, the luciferase gene, and the equorin gene.
- the taumarin gene can be used.
- the evening targeting vector for homologous recombination is constructed as follows. That is, the fragment obtained by cleaving the chromosome-derived SMP30 isolated as described above with an appropriate restriction enzyme is ligated in a suitable order to a chimeric gene, a reporter gene, a DT-A cassette, and the like. Let it. At this time, if necessary, a synthesized linker: DNA may be used. In addition, a part of the fragment of the isolated chromosome-derived SMP30 gene can be amplified by removing PCI as necessary.
- Targeting vector for homologous recombination Can be easily prepared by ordinary DNA recombination techniques. Next, the homologous recombination target vector is linearized and introduced into appropriate cells.
- ES cells embryonic stem cells
- ES cells embryonic stem cells
- the cells into which the targeting vector has been incorporated can be selected by the expression of the gene in the vector.
- the marker is a drug resistance gene
- it can be selected by culturing in the presence of the drug for an appropriate period.
- Homologous recombination in the selected cells can be confirmed by the PCR method or Southern hybridization.
- the ratio of homologous recombination is higher than usual, but in any case, it is necessary to confirm the site of recombination when confirming the insertion.
- Cells eg, ES cells
- ES cells eg, ES cells
- agglutination method allowed to develop to the blastocyst stage, and then transplanted into the pup of a pseudopregnant animal.
- chimeric offspring e.g, ES cells
- Offspring of these chimeric animals whose germ cells are derived from ES cells can be crossed with wild type to obtain heterozygous SMP30 gene-deficient animals.
- the obtained SMP30 hetero-deficient animals can be crossed to homozygous deletion.
- the genotype of these animals can be confirmed by analyzing the chromosomal DNA obtained from a part of the body of the animal (for example, the tip of the tail) by a PCR method, a Southern hybridization method, or the like.
- the animal of the present invention can be bred by the same method as a normal animal.
- SMP30 deficient non-human animals can be used to elucidate diseases caused by SMP30 deficiency and their therapeutic methods.
- an antigen-binding fragment refers to a fragment that does not bind to an antigen (eg, an Fc fragment).
- rodents such as mice and rats are generally used for the production of antibodies, but as described above, the amino acid sequence of SMP30 is used in humans, mice, rats, and rabbits. And maintain very high homology (Fujita 3 ⁇ 4, Mech Aging Dev. Vol.
- Antibody can be prepared by Whether an antibody recognizes multiple antigens as a common antigen depends on the species
- SMP30 which is a cornerstone of the antigen, has been reported as the SMP30 amino acid sequence of humans, mice, rats, rabbits, rabbits, birds, etc. As long as they have homology, they include sequences other than those already reported, those not derived from these animals, and those modified by addition, substitution, deletion, or insertion of an amino acid.
- SMP30 for example,
- amino acid sequence of the rat described in the NCB I access number D 31662 previously reported; (2) one or several amino acids in the amino acid sequence of the rat described in the previously reported NCB I access number D 31662 Proteins having amino acids with added, substituted, deleted or inserted residues are included.
- the addition, substitution, deletion, or insertion of amino acids is usually 1 to about 90, preferably 1 to about 60, more preferably 1 to about 30, more preferably 1 to about 15, More preferably, the number is one to several.
- SMP30 used as an antigen in the present invention may be any of the previously reported sequences, such as the above-described sequence of the rat, force (NCB I accession number AB 033368), mouse (Q 64374 or D 86217), mouse (AB 035446), It has homology of 70% or more, preferably 80% or more, more preferably 90% or more, further preferably 95% or more with the amino acid sequence of human (D31815) or the like. The proportion of what is called “high homology” is probably left to the researcher's subjective opinion, but proteins that are more than 70% homologous at the amino acid level are generally “evolved very well”.
- the homology is more than 60% between mammals and more than 50% between vertebrates, it is probable that antibody production is probabilistically difficult.For experiments, polyclonal antibodies must be used, and those with low sensitivity must be used. Absent. Therefore, not only in SMP30 but also in the production of antibodies of highly homologous proteins, it is necessary to create a defective channel and use it as an antibody. This is because, since the protein is completely difficult for deficiency, the portion having protein homologue can also be used as a bitmap. In the present invention, the amino acid homology between male and female is more than 40%.
- amino acids having a vertebral vertebrae with an affinity of 50% W_h are more advantageous, and those having a homology of 'I and a life of 60% or more are particularly powerful.
- the present invention is more effective when the homology of amino acids during sleep is 50% & ⁇ , and when the homology of amino acids is 60% ⁇ ⁇ .
- ⁇ in which the homology of amino acids among mammals is 70% or more is particularly nuclear. That is, if the homology between objects is 40% or more, or the homology between mammals is 50% or more, homology is higher in rodents actually used, and most of the ages are antibodies.
- the present invention provides an extremely effective means for producing an antibody of a protein that is conserved between species.
- This antibody is expected to have higher versatility than the conventional one. That is, if the prepared antibody is an antibody having an amino acid sequence portion conserved between different species as an epitope, only one kind of the antibody will react with any kind of the same kind of protein. This is of course applicable to polyclonal antibodies reacting with multiple shrimp totopes, but it is possible to select antibody-producing cells having such a wide reactivity in producing monoclonal antibodies. . In addition, since the antigen is completely foreign to the immunized animal, it is expected that highly sensitive polyclonal antibodies will be produced. That is, every part of the protein introduced into the body as an antigen is effective as an epitope, and a myriad of combinations of antibodies that react with them show stronger reactions.
- mice the SMP30 gene is located on the X chromosome, so males of first-generation SMP30-deficient mice have a genotype (Y /-) and females have a heterogeneous (+/-) genotype in most cases. Becomes This first-generation (Y / —) male has an SMP30 deficient phenotype, but recognizes exogenous SMP30 as a heterologous protein because it has acquired tolerance in the mother's womb. do not do. In the next generation of mice, both males (Y /-) and homozygous females (1-/-) have a heterozygous mother (+ Z-).
- the antibody thus obtained is used, for example, for measuring the amount of SMP30 in body fluids and tissues.
- SMP30 is present in all body fluids and tissues such as blood, urine, stomach fluid, gastric fluid, bile, and cerebrospinal fluid, and the amount increases or decreases due to various organ disorders. These can be measured using an anti-SMP30 antibody.
- any of general measuring methods such as ELISA and sandwich method may be used.
- the developed measurement method is effective across species as described above, and can be used not only for humans, but also for livestock, pets, experimental animals, and the like.
- the above-mentioned antibodies can be used immunohistologically in pathological tissue diagnosis according to a standard method.
- SMP30 is expressed in almost all organs, but has strong expression especially in hepatocytes and renal tubular epithelial cells, which are major target organs for drug disorders. Since these target cells are vulnerable to drug damage in SMP-deficient animals, It is possible to detect side effects on organs with high sensitivity. Animals deficient in SMP30 are effective as highly sensitive detection models for side effects in drug development. In animal experiments, it is known that oxidative stress reduces the expression of SMP30. In addition, the expression of SMP30 decreases with aging, and as a result, the amount of SMP30 protein in blood also decreases (Fujita et al., Biochim Biophys Acta, Vol. 1308, 49-57, 1996). It is presumed that cell aging is enhanced by stress. For this reason, for example, by measuring the amount of SMP30 protein in blood, a decrease in SMP30 expression can be used as a parameter for the degree of aging.
- NCB I access number X
- pGM6 SMP 30 (NCBI accession number; U32170 (DDB J)) of dienomic DNA derived from C57BL / 6 mouse (Fujita et al., Biochim Biophys Vol. 1308, 49-57, 1996) was used as a mirror type to Set the primer (SEQ ID No: 3) in the direction 3 from C1aI of the third exon, and set the antisense primer (SEQ ID No: 4) in the direction 5 about 2 Kbp downstream of it. A 2 Kbp fragment (short arm) was prepared by PCI removal ( Figure 1).
- ES cells Mouse embryonic stem cells (ES cells) (1 [2 cell lines, ⁇ chromosome) (Yagi et al., Anal Biochem, Vol. 214, ⁇ 0-76, 1993) are cultured by an electroporation method. The evening getter, which had been linearized by the Not I treatment described above, was introduced into the ES cells by the racion method. After the electroporation, the cells were selectively cultured in a medium containing G418 to obtain 502 neomycin-resistant clones (evening-ES cells into which the targeting vector was introduced). The presence or absence of homologous recombination was confirmed for these 502 clones by the Southern hybridization method.
- mice Male and female ICR mice were mated to collect 8-cell embryos from pregnant mice, plugs were confirmed, goblet cysts were removed from the uterus of female mice that appeared to be pregnant, and 8-cell embryos were obtained. Then, ES cells (# 41) in which homologous recombination of the SMP30 gene had occurred were adsorbed to the embryo surface by the aggregation method. After culturing for an additional day, those that developed in the goblet blastocysts were transplanted into the uterus of the foster mother. The genotype of the born chimeric mouse was It was confirmed by the hybridization and the PCR method.
- DNA extracted from mouse liver was digested with the restriction enzyme EcoRI, and a 7-Kbp fragment was identified.
- TS3 SEQ ID No: 5
- TA4 SEQ ID No: 6
- a band of 323 bp due to the combination of NE01 (SEQ ID No: 7) and TA4 and a band of 1363 bp due to the combination of TS3 and TA4 were observed.
- the expression of the SMP30 gene in the liver of a mouse in which homologous recombination occurred in the SMP30 gene and a mouse in which the homologous recombination did not occur was analyzed by Western blotting.
- Western plot was performed using a polyclonal antibody prepared by immunizing rabbits with rat SMP30, a band was observed at a site of about 30 KDa corresponding to the molecular weight of SMP30 in wild-type mice. None was found in the deficient mice. From these results, it was confirmed that SMP30-deficient mice were established by homologous recombination of the SMP30 gene.
- Example 4 It was confirmed whether highly reactive anti-SMP30 polyclonal antibodies could be obtained using SMP30-deficient mice in which the effectiveness of anti-SMP30 antibody production in SMP30-deficient mice was confirmed.
- Polyclonal antibody production is a widely and generally known technique in the field of biology.
- the mice used were M1 of the first generation; F1 and M2 and F2 born of their parents, and M3 of these parents.
- the genotype was Ml (Y / Y / —), F 1 (+/-), M2 (Y / —), F 2 (one / one), M3 (Y / —) (SMP 30 is located on the X chromosome, The mouse genotype is Y /-).
- the myeloma cells PX 63 Ag 8. 653 American Type Cu 1 ture Co l lect ion (Rockvi l le, MD, USA) and type hand than, the fusion as day 5-1 Ox 10 7 cells are obtained 1 Culture was started a week ago. On the day, the cells were centrifuged at 1200 rpm for 5 minutes at 4 ° C, Eagle MEM was added to the precipitate, the cells were resuspended and centrifuged, and 20 ml of Eagle MEM was added and suspended, and the number of cells was counted.
- the spleen removed from the immunized mouse was scraped out of cells on a stainless steel mesh, washed with an Eagle MEM (Nissui), and the cells were dropped on a culture dish.
- the cell suspension was filtered through glass wool, and the filtrate was centrifuged at 4 ° C and 1000 rpm for 5 minutes to collect the cells, and 40 ml of Eagle's MEM was added to the cells. Counted the number.
- the myeloma cells and spleen cells were mixed at a ratio of 1: 2 and centrifuged at 1000 rpm at 4 ° C for 5 minutes. The supernatant was removed, 1 ml of PEG-Eagle MEM was gradually added to loosen the cells, and then Eagle MEM 3 Oml at 37 ° C was gradually added. After centrifugation (800 rpm, room temperature, 5 minutes), remove the supernatant, add 1 Oml of 10% FCS + RPMI-1640 at 37 ° C, leave it at 37 ° C for 60 minutes, close the lid, and loosen it on the top and bottom. Shake to loosen the precipitate. 4% of 10% FCS + RPMI-1640 was added, and the mixture was dispensed in 25 ml portions, and 10% FCS + RPMI-1640 was added to make 5 Oml.
- HAT On the day after the fusion, 2% HAT was prepared by adding 10% FCS + RPMI-164 (H;: 50 ⁇ HAT (SI GMA)), and 10 Ol was added to each well, followed by 100 ⁇ 1 every 2 or 3 days. The soil was changed, and 10 days after the fusion, the cells were cultured in 2xHT / l 0% FCS + RPMI-1640.
- mice severely immunodeficient mice. Two weeks later, ascites was collected and 30% sulfur After immunoprecipitation and dialysis with PBS, the reactivity with SMP30 in the liver cells of mice, rats, humans, rabbits, and rabbits was confirmed by Western plotting. Was shown, suggesting that it also reacts to sites that are highly conserved among species.
- Antibodies obtained using normal mice generally use a site different from the SMP30 amino acid sequence of their own, so the monoclonal antibody used was an SMP30-deficient mouse. Therefore, it was presumed that the antibody was obtained.
- the animal in which the function of SMP30 of the present invention is deficient is useful for analyzing the biological function of SMP30, relating to disease, and searching for a treatment method.
- SMP30 is reduced in systemic organs with aging, it is also useful for elucidating the mechanism of age-related diseases. Also, since hepatocytes are fragile, they can be used as a side effect screening for new drugs. Furthermore, anti-SMP30 antibodies produced using SMP30-deficient animals are more reactive than wild-type antibodies, are effective across species, and have been developed to measure SMP3 ⁇ . Can be widely applied.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- General Health & Medical Sciences (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- Veterinary Medicine (AREA)
- Environmental Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- General Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Animal Husbandry (AREA)
- Biodiversity & Conservation Biology (AREA)
- Plant Pathology (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
L'invention concerne un animal non humain à protéine-marqueur de sénescence 30 défectueuse, chez qui le dysfonctionnement de la fonction SMP30 est dû à la suppression d'au moins une partie de la séquence ADN dans le gène SMP30 chromosomique. Selon l'invention, on insère une autre séquence ou on remplace au moins une partie de la séquence ADN par une autre séquence ou encore on associe ces procédures.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2000322234A JP2004267002A (ja) | 2000-10-23 | 2000-10-23 | セネッセンスマーカープロテイン３０欠損動物、抗体およびその作製方法 |
| JP2000-322234 | 2000-10-23 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| WO2002034041A1 true WO2002034041A1 (fr) | 2002-05-02 |
Family
ID=18800142
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/JP2001/009243 WO2002034041A1 (fr) | 2000-10-23 | 2001-10-22 | Animal non humain a proteine-marqueur de la senescence 30 defectueuse, anticorps et son procede de production |
Country Status (2)
| Country | Link |
|---|---|
| JP (1) | JP2004267002A (fr) |
| WO (1) | WO2002034041A1 (fr) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2006044336A1 (fr) | 2004-10-12 | 2006-04-27 | Translational Medicines, Inc. | Accroissement de la diversite des anticorps monoclonaux produits contre un antigene |
| EP1437043A4 (fr) * | 2001-09-20 | 2007-01-17 | Japan Science & Tech Agency | Modele animal presentant une surexpression de regucalcine |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2007054042A (ja) * | 2005-07-26 | 2007-03-08 | Japan Science & Technology Agency | インターフェロン誘導分子ｉｐｓ−１ |
-
2000
- 2000-10-23 JP JP2000322234A patent/JP2004267002A/ja active Pending
-
2001
- 2001-10-22 WO PCT/JP2001/009243 patent/WO2002034041A1/fr active Application Filing
Non-Patent Citations (6)
| Title |
|---|
| CASTROP J. ET AL., IMMUNOBIOL., vol. 193, 1995, pages 281 - 287, XP001013453 * |
| DECLERCK P.J. ET AL., J. BIOL. CHEM., vol. 270, 1995, pages 8397 - 8400, XP002174630 * |
| ENOMOTO N. ET AL., HEPATOLOGY, vol. 32, no. 4, PT. 2, 2000, pages 323A, XP002907860 * |
| ENOMOTO N. ET AL., HEPATOLOGY, vol. 69, no. 4, PT. 2, 1999, pages 510A, XP002907861 * |
| FUJITA T. ET AL., BIOCHIMICA ET BIOPHYSICA ACTA, vol. 1308, 1996, pages 49 - 57, XP002907863 * |
| FUJITA T. ET AL., MECHANISMS OF AGEING AND DEVELOPMENT, vol. 107, 1999, pages 271 - 280, XP002907862 * |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1437043A4 (fr) * | 2001-09-20 | 2007-01-17 | Japan Science & Tech Agency | Modele animal presentant une surexpression de regucalcine |
| US7355093B2 (en) | 2001-09-20 | 2008-04-08 | Japan Science And Technology Agency | Model animal with overexpression of regucalcin |
| WO2006044336A1 (fr) | 2004-10-12 | 2006-04-27 | Translational Medicines, Inc. | Accroissement de la diversite des anticorps monoclonaux produits contre un antigene |
| US8389793B2 (en) | 2004-10-12 | 2013-03-05 | Acton Biotech Consulting | Methods for increasing the diversity of monoclonal antibodies produced against an antigen |
Also Published As
| Publication number | Publication date |
|---|---|
| JP2004267002A (ja) | 2004-09-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US6187992B1 (en) | Transgenic mouse having a disrupted amyloid precursor protein gene | |
| KR20040015711A (ko) | 약물학적 및 독성학적 연구용 트랜스제닉 비인간 동물 | |
| WO2006132788A2 (fr) | Nouvelles disruptions geniques, nouvelles compositions et nouveaux procedes s'y rapportant | |
| US20200359610A1 (en) | Humanized transgenic animal | |
| US6452065B2 (en) | Transgenic mouse expressing non-native wild-type and familial Alzheimer's Disease mutant presenilin 1 protein on native presenilin 1 null background | |
| JP2001211782A (ja) | ｔｏｂ遺伝子欠損ノックアウト非ヒト哺乳動物 | |
| WO2002034041A1 (fr) | Animal non humain a proteine-marqueur de la senescence 30 defectueuse, anticorps et son procede de production | |
| KR101954726B1 (ko) | 펜드리드 증후군 동물 모델 및 이의 제조 방법 | |
| US20220217956A1 (en) | Rodent Model Of Increased Bone Mineral Density | |
| JP6267986B2 (ja) | ヒトの特定分子と結合する分子標的物質のｉｎｖｉｖｏ評価法 | |
| JP2012125235A (ja) | 間質性肺炎モデル及びその用途 | |
| JP4374438B2 (ja) | ｒａｂ８ａ遺伝子欠損マウス | |
| WO2006016692A1 (fr) | Animal non-humain assommé | |
| JP4217782B2 (ja) | ロスモンド・トムソン症候群の特徴を示すマウス及びその作製方法 | |
| JP4940477B2 (ja) | Ｏａｓｉｓ遺伝子欠損マウス | |
| US7541511B2 (en) | Mouse exhibiting characteristics of Rothmund-Thomson syndrome and preparation method thereof | |
| JP2009225697A (ja) | Ａｂｃａ１２遺伝子機能欠損マウス | |
| JP2006314242A (ja) | 哺乳動物由来の変異ｓｄｈｃ遺伝子を有する遺伝子組み換え動物 | |
| JP2007508814A (ja) | ヒトｂ１ブラジキニン受容体タンパク質を選択的に発現するトランスジェニックげっ歯動物 | |
| JP2006042683A (ja) | ニューログリカンｃ遺伝子の発現が抑制された非ヒト動物 | |
| JP2006025647A (ja) | Ｆｓｐ２７ノックアウト動物 | |
| JP2003169679A (ja) | ヒトβ３受容体発現動物 | |
| JP2006325452A (ja) | Ｔｚｆ／ｔｚｆ−ｌ遺伝子ノックアウト非ヒト哺乳動物、その作製方法、およびその利用方法 | |
| WO2007080710A1 (fr) | Souris déficiente en gène transporteur vésiculaire du gaba | |
| JP2004298180A (ja) | ゲノムが改変されたマウス |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
| 122 | Ep: pct application non-entry in european phase |